We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ex-Pfizer Business Development Director Joins Australian Drug Developer Agenix

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Agenix Limited has announced the appointment of Dr Paul Resnick as Business Advisor initially focusing on the Company’s revolutionary blood clot diagnostic, ThromboView®.

Dr Resnick is the former Vice President of Business Development at privately held US-based biotechnology business Intellikine Inc where he played a key role in securing a $489 million program licensing deal and the subsequent sale of the business in December 2011 to Japan’s Takeda Pharmaceutical Co for $310 million.

Before joining Intellikine, Dr Resnick was Senior Director of Worldwide Business Development at Pfizer Inc.

He previously held roles at Rinat Neuroscience, InterMune, Roche Pharmaceuticals and practiced medicine. At Rinat Neuroscience, he played a key role in its acquisition by Pfizer Inc.

Agenix Chairman and Chief Executive Officer Nicholas Weston said, "Paul adds significant depth and experience to our team and will provide strategic guidance and negotiation support as we progress our promising commercial and clinical programs.”

Weston continued, “Agenix is continuously engaged with potential strategic corporate partners in multiple geographies. Paul will help us manage this important process in a timely and efficient manner to achieve the best possible results that create shareholder value.”

Dr Resnick said “I see significant unrecognized potential and value in Agenix and the exciting assets it has developed. There is a compelling proposition in ThromboView's strong clinical safety and efficacy profile and its potential value in a range of clinical applications.”